In clinical practice, it is recommended to strengthen lymphoma screening for PLWH with a persistently inverted CD4/CD8 ratio and to incorporate emerging prognostic models into therapeutic decision-making and follow-up monitoring. The gene discussed is CD8A; the disease is lymphoma.